Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Pancreatology ; 23(7): 777-783, 2023 Nov.
Article in English | MEDLINE | ID: mdl-37778935

ABSTRACT

OBJECTIVE: There is an unmet clinical need for effective, targeted interventions to prevent post-ERCP pancreatitis (PEP). We previously demonstrated that the serine-threonine phosphatase, calcineurin (Cn) is a critical mediator of PEP and that the FDA-approved calcineurin inhibitors, tacrolimus (Tac) or cyclosporine A, prevented PEP. Our recent observations in preclinical PEP models demonstrating that Cn deletion in both pancreatic and hematopoietic compartments is required for maximal pancreas protection, highlighted the need to target both systemic and pancreas-specific Cn signaling. We hypothesized that rectal administration of Tac would effectively mitigate PEP by ensuring systemic and pancreatic bioavailability of Tac. We have tested the efficacy of rectal Tac in a preclinical PEP model and in cerulein-induced experimental pancreatitis. METHODS: C57BL/6 mice underwent ductal cannulation with saline infusion to simulate pressure-induced PEP or were given seven, hourly, cerulein injections to induce pancreatitis. To test the efficacy of rectal Tac in pancreatitis prevention, a rectal Tac suppository (1 mg/kg) was administered 10 min prior to cannulation or first cerulein injection. Histological and biochemical indicators of pancreatitis were evaluated post-treatment. Pharmacokinetic parameters of Tac in the blood after rectal delivery compared to intravenous and intragastric administration was evaluated. RESULTS: Rectal Tac was effective in reducing pancreatic injury and inflammation in both PEP and cerulein models. Pharmacokinetic studies revealed that the rectal administration of Tac helped achieve optimal blood levels of Tac over an extended time compared to intravenous or intragastric delivery. CONCLUSION: Our results underscore the effectiveness and clinical utility of rectal Tac for PEP prophylaxis.


Subject(s)
Cholangiopancreatography, Endoscopic Retrograde , Pancreatitis , Animals , Mice , Administration, Rectal , Anti-Inflammatory Agents, Non-Steroidal , Ceruletide , Cholangiopancreatography, Endoscopic Retrograde/adverse effects , Cholangiopancreatography, Endoscopic Retrograde/methods , Mice, Inbred C57BL , Pancreatitis/etiology , Pancreatitis/prevention & control , Tacrolimus/administration & dosage , Tacrolimus/therapeutic use
2.
Pancreatology ; 23(4): 333-340, 2023 Jun.
Article in English | MEDLINE | ID: mdl-37031049

ABSTRACT

OBJECTIVE: There is an urgent need for safe and targeted interventions to mitigate post-ERCP pancreatitis (PEP). Calcineurin inhibitors (CnIs) offer therapeutic promise as calcineurin signaling within acinar cells is a key initiating event in PEP. In previous proof-of-concept studies using experimental models, we showed that concurrent intra-pancreatic ductal administration of the CnIs, tacrolimus (Tac) or cyclosporine A (CsA) with the ERCP radiocontrast agent (RC) prevented PEP. To translate this finding clinically, we investigated potential toxic effects of intraductal delivery of a single-dose RC-CnI formulation on endocrine pancreas function and systemic toxicities in a preclinical PEP model. METHODS: C57BL/6J mice underwent ductal cannulation and received a single, intra-pancreatic ductal infusion of RC or RC with Tac or CsA (treatment groups) or underwent ductal cannulation without infusion ('sham' group). To assess endocrine function, intraperitoneal glucose tolerance test (IPGTT) was performed at two days before infusion and on day 2 and 14 post-surgery. To evaluate off-target tissue toxicities, renal and hepatic function-related parameters including blood urea nitrogen, plasma creatinine, potassium, aspartate aminotransferase, alanine aminotransferase, and total bilirubin were measured at the same time-points as IPGTT. Histological and biochemical indicators of pancreas injury and inflammation were also evaluated. RESULTS: No abnormalities in glucose metabolism, hepatic or renal function were observed on day 2 or 14 in mice administered with intraductal RC or RC with Tac or CsA. CONCLUSION: Intraductal delivery of RC-CnI formulation was safe and well-tolerated with no significant acute or subacute endocrine or systemic toxicities, underscoring its clinical utility to prevent PEP.


Subject(s)
Calcineurin Inhibitors , Pancreatitis , Mice , Animals , Calcineurin Inhibitors/therapeutic use , Calcineurin Inhibitors/pharmacology , Cholangiopancreatography, Endoscopic Retrograde/adverse effects , Mice, Inbred C57BL , Tacrolimus/therapeutic use , Tacrolimus/pharmacology , Cyclosporine/therapeutic use , Pancreatitis/etiology , Pancreatitis/prevention & control , Pancreatitis/pathology , Contrast Media
3.
Pancreatology ; 22(6): 678-682, 2022 Sep.
Article in English | MEDLINE | ID: mdl-35872075

ABSTRACT

Endoscopic retrograde cholangiopancreatography (ERCP) is commonly performed for the management of pancreaticobiliary disorders. The most troublesome ERCP-associated adverse event is post-ERCP pancreatitis (PEP), which occurs in up to 15% of all patients undergoing ERCP. A substantial body of preclinical data support a mechanistic rationale for calcineurin inhibitors in preventing PEP. The findings are coupled with recent clinical data suggesting lower rates of PEP in patients who concurrently use the calcineurin inhibitor tacrolimus (e.g., solid organ transplant recipients). In this review, we will firstly summarize data in support of testing the use of tacrolimus for PEP prophylaxis, either in combination with rectal indomethacin or by itself. Secondly, we propose that administering tacrolimus through the rectal route could be favorable for PEP prophylaxis over other routes of administration.


Subject(s)
Cholangiopancreatography, Endoscopic Retrograde , Pancreatitis , Administration, Rectal , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Calcineurin Inhibitors/therapeutic use , Cholangiopancreatography, Endoscopic Retrograde/adverse effects , Humans , Pancreatitis/drug therapy , Pancreatitis/etiology , Pancreatitis/prevention & control , Risk Factors , Tacrolimus/therapeutic use
4.
Gastroenterology ; 159(3): 1036-1050.e8, 2020 09.
Article in English | MEDLINE | ID: mdl-32445858

ABSTRACT

BACKGROUND & AIMS: Calcineurin is a ubiquitously expressed central Ca2+-responsive signaling molecule that mediates acute pancreatitis, but little is known about its effects. We compared the effects of calcineurin expression by hematopoietic cells vs pancreas in mouse models of pancreatitis and pancreatitis-associated lung inflammation. METHODS: We performed studies with mice with hematopoietic-specific or pancreas-specific deletion of protein phosphatase 3, regulatory subunit B, alpha isoform (PPP3R1, also called CNB1), in mice with deletion of CNB1 (Cnb1UBC△/△) and in the corresponding controls for each deletion of CNB1. Acute pancreatitis was induced in mice by administration of caerulein or high-pressure infusion of radiocontrast into biliopancreatic ducts; some mice were also given intraductal infusions of an adeno-associated virus vector that expressed nuclear factor of activated T -cells (NFAT)-luciferase into pancreas. Pancreas, bone marrow, liver, kidney, heart, and lung were collected and analyzed by histopathology, immunohistochemistry, and immunoblots; levels of cytokines were measured in serum. Mouse and human primary pancreatic acinar cells were transfected with a vector that expressed NFAT-luciferase and incubated with an agent that blocks interaction of NFAT with calcineurin; cells were analyzed by immunofluorescence. Calcineurin-mediated neutrophil chemotaxis and reactive oxygen species production were measured in neutrophils from mice. RESULTS: Mice with hematopoietic-specific deletion of CNB1 developed the same level of local pancreatic inflammation as control mice after administration of caerulein or infusion of radiocontrast into biliopancreatic ducts. Cnb1UBC△/△ mice or mice with pancreas-specific deletion of CNB1 developed less severe pancreatitis and reduced pancreatic inflammation after administration of caerulein or infusion of radiocontrast into biliopancreatic ducts compared with control mice. NFAT was activated in pancreas of Swiss Webster mice given caerulein or infusions of radiocontrast into biliopancreatic ducts. Blocking the interaction between calcineurin and NFAT did not reduce pancreatic acinar cell necrosis in response to caerulein or infusions of radiocontrast. Mice with hematopoietic-specific deletion of CNB1 (but not mice with pancreas-specific deletion of CNB1) had reduced infiltration of lung tissues by neutrophils. Neutrophil chemotaxis and production of reactive oxygen species were decreased after incubation with a calcineurin inhibitor. CONCLUSIONS: Hematopoietic and neutrophil expression of calcineurin promotes pancreatitis-associated lung inflammation, whereas pancreatic calcineurin promotes local pancreatic inflammation. The findings indicate that the protective effects of blocking or deleting calcineurin on pancreatitis are mediated by the source of its expression. This information should be used in the development of strategies to inhibit calcineurin for the prevention of pancreatitis and pancreatitis-associated lung inflammation.


Subject(s)
Acute Lung Injury/immunology , Calcineurin Inhibitors/therapeutic use , Calcineurin/metabolism , Calcium-Binding Proteins/metabolism , Muscle Proteins/metabolism , Pancreatitis/immunology , Acinar Cells/metabolism , Acute Lung Injury/blood , Acute Lung Injury/pathology , Acute Lung Injury/prevention & control , Animals , Bone Marrow Cells/immunology , Bone Marrow Cells/metabolism , Calcineurin/genetics , Calcineurin/immunology , Calcium-Binding Proteins/genetics , Cells, Cultured , Ceruletide/administration & dosage , Ceruletide/toxicity , Cytokines/blood , Cytokines/metabolism , Disease Models, Animal , Female , Humans , Male , Mice , Mice, Transgenic , Muscle Proteins/genetics , NFATC Transcription Factors/antagonists & inhibitors , NFATC Transcription Factors/metabolism , Neutrophils/immunology , Neutrophils/metabolism , Pancreas/cytology , Pancreas/immunology , Pancreas/metabolism , Pancreatitis/chemically induced , Pancreatitis/complications , Pancreatitis/drug therapy , Primary Cell Culture
5.
Phytochemistry ; 71(10): 1085-94, 2010 Jul.
Article in English | MEDLINE | ID: mdl-20483437

ABSTRACT

Profiling of metabolites is a rapidly expanding area of research for resolving metabolic pathways. Metabolic fingerprinting in medicinally important plants is critical to establishing the quality of herbal medicines. In the present study, metabolic profiling of crude extracts of leaf and root of Withania somnifera (Ashwagandha), an important medicinal plant of Indian system of medicine (ISM) was carried out using NMR and chromatographic (HPLC and GC-MS) techniques. A total of 62 major and minor primary and secondary metabolites from leaves and 48 from roots were unambiguously identified. Twenty-nine of these were common to the two tissues. These included fatty acids, organic acids, amino acids, sugars and sterol based compounds. Eleven bioactive sterol-lactone molecules were also identified. Twenty-seven of the identified metabolites were quantified. Highly significant qualitative and quantitative differences were noticed between the leaf and root tissues, particularly with respect to the secondary metabolites.


Subject(s)
Plant Leaves/metabolism , Plant Roots/metabolism , Withania/metabolism , Chromatography, High Pressure Liquid , Gas Chromatography-Mass Spectrometry
SELECTION OF CITATIONS
SEARCH DETAIL
...